Aib substitution is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-05-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | free base, without counter-ion |
| Molecular weight | About 4114 Da | peptide backbone plus attached lipid chain |
| Plasma half-life | About 165 hours | supports once-weekly dosing in humans |
| Plasma protein binding | Greater than 99 percent | attributed mainly to serum albumin |
| Receptor target | GLP-1 receptor | Gs-coupled, raises intracellular cyclic AMP |
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.
Material described as research-grade is not necessarily manufactured to pharmaceutical standards, and purity figures depend on the method used to obtain them. A certificate of analysis states the measured purity, the analytical technique, and the batch identifier, but the underlying data are not always included. Independent testing by a second laboratory is a common way to confirm identity and purity. Uncertainties remain about how storage history affects long-term stability, and about how well results from one laboratory transfer to another. Documentation of handling conditions supports comparison between batches.
Peptides are sensitive to temperature, light, oxygen, and repeated freeze-thaw cycles. Semaglutide in dry form is generally held at refrigerated temperatures, while reconstituted solutions require a defined short-term storage window. Vials should be kept in secondary packaging to limit photodegradation, and exposure to alkaline conditions is avoided because it accelerates chemical degradation. Adsorption to glass and some plastics can reduce the measured concentration of dilute solutions, so low-binding polypropylene containers are preferred for analytical work. Each transfer step introduces a small risk of contamination, and closed handling practices reduce that risk.
Routine characterisation of the peptide relies on reversed-phase high-performance liquid chromatography, often paired with ultraviolet detection near 214 nanometres. Related substances such as deamidated, oxidised, and truncated sequences elute at characteristic positions and are quantified by area percentage. Electrospray ionisation mass spectrometry confirms the molecular mass and can resolve some closely related variants. Peptide mapping after enzymatic digestion provides sequence-level verification and is useful when a full identity profile is required. Method parameters such as column chemistry, gradient, and mobile-phase pH influence the separation and must be reported alongside results.
Nylons can also be synthesized from dinitriles using acid catalysis. For example, this method is applicable for preparation of nylon 1,6 from adiponitrile, formaldehyde and water. Additionally, nylons can be synthesized from diols and dinitriles using this method as well.
Equine metabolic syndrome (EMS) is an endocrinopathy affecting horses and ponies. It is of primary concern due to its link to obesity, insulin dysregulation, and subsequent laminitis. There are some similarities in clinical signs between EMS and pituitary pars intermedia dysfunction, also known as PPID or Cushing's disease, and some equines may develop both, but they are not the same condition, having different causes and different treatment.
=== Protein–polymer particles designed for drug delivery === The absorption of proteins for particles in physiological fluids can greatly affect the subsequent medical performance of particles in vivo. Nonspecific protein adsorption can be controlled in vivo by modifying the nanoparticle surface with a non-toxic, biocompatible protein possessing tolerable antigenic properties such as albumin. The high recognition ability of proteins can enable high delivery efficiency. Protein-polymer particles have potential to deliver drugs to specific regions of the body using the inherent biorecognition property at the protein interface. Additionally, in some cases the presentation of specific proteins on nanoparticle surfaces can be useful for aiding passage through impermeable biological barriers.
In 1893, Prof. Niels Ryberg Finsen (1860–1904) began to treat lupus vulgaris, a tubercular condition of the skin, in the direct mode with heat-filtered light from a carbon arc lamp. He established the Phototherapy treatment at the Whitechapel Hospital in London, which had a Light Department in the first decade of the 20th century. His activity had royal patronage, and Niels Ryberg Finsen received the Nobel Prize in 1903. In 1894, neurologist and psychiatrist Edward Flatau published a human brain atlas, "Atlas of the Human Brain and the Course of the Nerve-Fibres," which consisted of long-exposure photographs of fresh brain sections. It contained an overview of the knowledge of the time on the fibre pathways in the central nervous system. In 1924, the German psychiatrist Hans Berger attached electrodes to the scalp and detected small currents in the brain. In the 1940s, the US War Department investigated the use of electrical stimulation and used so-called "galvanic exercises" on the atrophied hands of patients with ulnar nerve damage from wound surgery, not only to slow and prevent atrophy, but also to restore muscle mass and strength. In the mid-20th century, the scientific study of neuromodulation in humans expanded significantly. Neurologist Professor Spiegel and neurosurgeon Professor Weissys of Temple University presented a stereotactic device to perform "ablation procedures" in humans; in 1947, "intraoperative electrical stimulation" was introduced to test the brain's target zone before surgery.
Phenylpiracetam, also known as fonturacetam (INNTooltip International nonproprietary name) and sold under the brand names Phenotropil, Actitropil, and Carphedon among others, is a stimulant and nootropic medication used in Russia and certain other Eastern European countries in the treatment of cerebrovascular deficiency, depression, apathy, attention, and memory problems, among other indications. It is also used in Russian cosmonauts to improve physical, mental, and cognitive abilities. The drug is taken by mouth. Side effects of phenylpiracetam include sleep disturbances among others. The mechanism of action of phenylpiracetam was originally unknown. However, it was discovered that (R)-phenylpiracetam is a selective atypical dopamine reuptake inhibitor in 2014. In addition, phenylpiracetam interacts with certain nicotinic acetylcholine receptors. Chemically, phenylpiracetam is a racetam and phenethylamine and is structurally related to piracetam. Phenylpiracetam was first described in 1983 by Bobkov Iu, et al. It was approved for medical use in Russia in 2003. Development of (R)-phenylpiracetam (code name MRZ-9547) in the West as a potential treatment for fatigue related to Parkinson's disease began by 2014. In addition to its medical use, phenylpiracetam is sold online as a nootropic.
Sources: en.wikipedia.org
Bimatoprost may be used to treat small or underdeveloped eyelashes. The medical term for this is treatment of hypotrichosis; however, the U.S. Food and Drug Administration (FDA) approval is for purely cosmetic purposes (see Prostaglandin F receptor#Clinical significance).
HT-2157 (former development code SNAP-37889) is a drug which acts as a selective non-peptide antagonist for the receptor GAL-3, which is usually activated by the neuropeptide galanin. Blocking this receptor with HT-2157 produced increased serotonin release, as well as producing antidepressant and anxiolytic effects in animal studies, and it was also being researched for treatment of cognitive dysfunction. All human clinical trials were terminated due to safety concerns however, and new GAL-3 antagonists are now being sought instead.
hypotonic Describing a solution containing a low concentration of dissolved solutes relative to another solution, i.e. having negative osmotic pressure, such that solvent will tend to move by osmosis across a semipermeable membrane from the solution of lower solute concentration to the solution of higher concentration until both solutions have equal concentrations. In a cell where the intracellular cytosol is hypotonic relative to the surrounding extracellular fluid (which by definition is hypertonic relative to the cytosol), the solvent (water) will flow across the plasma membrane out of the cytosol, causing the cell to lose water until both sides of the membrane are isotonic. Cells placed in severely hypertonic environments may be at risk of shriveling and desiccating due to the sudden outflow.
Kissinger, who accompanied Nixon to China, spent much time talking to the suave Chinese Premier Zhou Enlai about Vietnam, pressing him to end the supply of arms to North Vietnam. The talks went nowhere as Zhou told Kissinger that the North Vietnamese played off China against the Soviet Union, and to cut off North Vietnam would allow it to fall into the Soviet sphere of influence. As the Chinese People's Liberation Army had been badly bloodied by the Red Army in a border war in 1969, Zhou stated that to face a two-front war with Chinese forces facing North Vietnam in the south and the Soviet Union in the north was not acceptable to his government. Zhou offered Kissinger only the vague message that China supported efforts to find peace in Vietnam while refusing to make any promises, though Kissinger also noted that Zhou declined to endorse North Vietnam's demands. Despite Nixon's coming visit, in late 1971, the Chinese drastically increased their military aid to North Vietnam and continued to send a massive amount of weapons south even as Nixon and Kissinger exchanged pleasantries with Mao and Zhou in Beijing. As usual, when the Chinese increased their supply of arms to North Vietnam, the Soviet Union did likewise, as both Communist states competed with one another for influence in Hanoi by trying to be the biggest supplier of weapons. On 30 March 1972, the PAVN launched the Easter Offensive that overran several provinces in South Vietnam while pushing the ARVN to the brink of collapse. By 1 April 1972, the 3rd ARVN division was retreating south with their families.
For example, an elevated neutrophil count (neutrophilia) is associated with bacterial infection, inflammation, and myeloproliferative disorders, while a decreased count (neutropenia) may occur in individuals who are undergoing chemotherapy or taking certain drugs, or who have diseases affecting the bone marrow. Neutropenia can also be caused by some congenital disorders and may occur transiently after viral or bacterial infections in children. People with severe neutropenia and clinical signs of infection are treated with antibiotics to prevent potentially life-threatening disease.
Sources: en.wikipedia.org
Native GLP-1 is a short-lived peptide cleared within one to two minutes by dipeptidyl peptidase-4 and related enzymes. Semaglutide keeps the receptor-binding backbone but adds substitutions and a lipid chain. These changes block the main cleavage site and allow reversible albumin binding, extending the half-life to roughly 165 hours.
Albumin is the most abundant protein in plasma and carries molecules that bear fatty-acid chains. Binding shields the peptide from renal filtration and from peptidases, keeping a circulating reservoir. Slow release from this reservoir produces sustained receptor occupancy and supports infrequent dosing.
The insulinotropic effect is glucose-dependent, meaning secretion increases mainly when glucose is elevated. This property is often described as lowering the chance of hypoglycaemia when the compound is used alone. Other glucose-lowering agents used at the same time can still cause low blood glucose.
Native GLP-1 is degraded within minutes by circulating enzymes. The synthetic version carries substitutions at positions that block enzymatic cleavage, plus a fatty acid side chain that promotes albumin binding. These two changes together extend circulation time from minutes to roughly a week.